Tag: Vaccine
Japan’s homegrown COVID-19 mRNA vaccine needs superior safety & efficacy data...
In 2021, leading mRNA vaccines, Comirnaty and Spikevax, generated combined sales of more than $54 billion globally and are expected to generate similar or greater sales in 2022
Hester plans capacity expansion for Goat Pox vaccine, to manufacture Lumpy...
The company will acquire the technology for Lumpy Skin disease vaccine from ICAR-IVRI to manufacture and commercialize the Lumpy Skin disease Vaccine
A drop of blood can now determine if a booster dose...
SMART and NTU Singapore develop a quick test kit to determine a person’s immunity against COVID-19 and its variants
Pfizer initiates Phase 3 Study of mRNA-based Influenza vaccine
First Phase 3 efficacy study to be conducted using an mRNA-based influenza vaccine; study will enroll 25,000 U.S. adults 18 years and older
Indonesia’s Bio Farma ready to produce IndoVac Covid-19 vaccines
The company collaborated with Baylor College of Medicine, a private, independent health sciences centre in Houston, Texas to develop IndoVac, a recombinant protein subunit vaccine produced from yeast
Intravacc releases more data on its intranasal SARS-CoV-2 vaccine candidate
Additional pre-clinical data of Avacc 10®indicate reduction in upper respiratory tract viral load and cross neutralization of variants of concern
AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData
The government’s decision to limit the drug’s supply to only COVID-19 prevention will still likely encourage its uptake, says GlobalData, a leading data and analytics company
Bharat Biotech’s iNCOVACC, world’s first Intra Nasal vaccine, gets emergency use...
Heterologous booster dose studies were conducted for safety and immunogenicity in ~875 subjects at 9 trial sites across India
Aurobindo Pharma to invest Rs 300 crore on mammalian cell culture...
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
CDSCO nod to Biological E’s pneumonia vaccine for infants
BE’s PCV14 is comparable in terms of serotype coverage for infants to the two pneumococcal conjugate vaccines Prevnar13 and Merck’s VAXNEUVANCE, which are currently approved globally